Joshua M Uronis
Overview
Explore the profile of Joshua M Uronis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
2539
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eisner J, Mayhew G, Davison J, Beebe K, Shibata Y, Guo Y, et al.
Clin Cancer Res
. 2023 May;
29(16):3203-3213.
PMID: 37233991
Purpose: The Piedmont study is a prospectively designed retrospective evaluation of a new 48-gene antifolate response signature (AF-PRS) in patients with locally advanced/metastatic nonsquamous (NS) non-small cell lung cancer (NSCLC)...
2.
Eisner J, Beebe K, Mayhew G, Shibata Y, Guo Y, Farhangfar C, et al.
Cancer Res Commun
. 2023 Mar;
2(8):894-903.
PMID: 36923304
Significance: Next-generation IL2 agents, designed for improved tolerability over traditional HD-IL2 (aldesleukin), are in clinical development. Retrospective molecular tumor profiling of patients treated with HD-IL2 or anti-PD-1 therapy provides insights...
3.
Mayhew G, Uronis J, Hayes D, Zevallos J
Front Oncol
. 2022 Sep;
12:954037.
PMID: 36147910
Patients with oral cavity squamous cell carcinoma (OCSCC) are predominantly human papillomavirus (HPV)(-), and treatment typically involves surgical resection ± neck dissection, followed by radiation ± chemotherapy. We previously described...
4.
Rose T, Weir W, Mayhew G, Shibata Y, Eulitt P, Uronis J, et al.
Br J Cancer
. 2022 Mar;
126(8):1237.
PMID: 35277660
No abstract available.
5.
Rose T, Weir W, Mayhew G, Shibata Y, Eulitt P, Uronis J, et al.
Br J Cancer
. 2021 Jul;
125(9):1251-1260.
PMID: 34294892
Background: FGFR3-altered urothelial cancer (UC) correlates with a non-T cell-inflamed phenotype and has therefore been postulated to be less responsive to immune checkpoint blockade (ICB). Preclinical work suggests FGFR3 signalling...
6.
Arthur J, Gharaibeh R, Muhlbauer M, Perez-Chanona E, Uronis J, McCafferty J, et al.
Nat Commun
. 2014 Sep;
5:4724.
PMID: 25182170
Enterobacteria, especially Escherichia coli, are abundant in patients with inflammatory bowel disease or colorectal cancer (CRC). However, it is unclear whether cancer is promoted by inflammation-induced expansion of E. coli...
7.
Arthur J, Gharaibeh R, Uronis J, Perez-Chanona E, Sha W, Tomkovich S, et al.
Sci Rep
. 2013 Oct;
3:2868.
PMID: 24100376
Although probiotics have shown success in preventing the development of experimental colitis-associated colorectal cancer (CRC), beneficial effects of interventional treatment are relatively unknown. Here we show that interventional treatment with...
8.
Arthur J, Perez-Chanona E, Muhlbauer M, Tomkovich S, Uronis J, Fan T, et al.
Science
. 2012 Aug;
338(6103):120-3.
PMID: 22903521
Inflammation alters host physiology to promote cancer, as seen in colitis-associated colorectal cancer (CRC). Here, we identify the intestinal microbiota as a target of inflammation that affects the progression of...
9.
Uronis J, Osada T, McCall S, Yang X, Mantyh C, Morse M, et al.
PLoS One
. 2012 Jun;
7(6):e38422.
PMID: 22675560
Mouse models have been developed to investigate colorectal cancer etiology and evaluate new anti-cancer therapies. While genetically engineered and carcinogen-induced mouse models have provided important information with regard to the...
10.
Allen I, Wilson J, Schneider M, Lich J, Roberts R, Arthur J, et al.
Immunity
. 2012 Apr;
36(5):742-54.
PMID: 22503542
In vitro data suggest that a subgroup of NLR proteins, including NLRP12, inhibits the transcription factor NF-κB, although physiologic and disease-relevant evidence is largely missing. Dysregulated NF-κB activity is associated...